Improving access to CAR-T cell therapies in ANZ

Did you know that only 4 of the 9 T cell immunotherapies approved in USA are approved in Australia? And that only one of these products made individually for each patient was ever manufactured here (but no longer is)?

CEO and Managing Director, Tim Oldham recently had the opportunity to discuss this at ANZ Biologics Festival. He proposed a blueprint to change this and discussed how AdAlta is aiming to help through its AdCella "East to West" cell therapy subsidiary. The blueprint has 5 elements:
✅ Design and develop better products with access in mind: AdCella's BZDS1901 is engineered to improve targeting and overcome immune suppression and can be manufactured in just two days without expensive viral vectors
✅ Facilitate commercial product licensing (adopt the regional specialty pharma model that has worked in other modalities): AdCella retains commercialisation rights for its products in Australia and New Zealand, ensuring local supply
✅ Increase/attract clinical development of these therapies (Australia is already very experienced and internationally regarded): by leveraging "Advantage Australia" as part of its "East to West" strategy, AdCella ensures that Australian patients get first access outside China/Asia to our novel therapies
✅ Facilitate "home grown" product development - carefully: several countries around the world, notably Spain, New Zealand, UK and Canada are taking proactive regulatory and other steps to close the "drug lag" to getting products approved. This requires great care to balance safety and manufacturing consistency against IP and incentives for novel product development
✅ Implement value chain enablers: continued evolution of regulatory frameworks, enabling introduction of advanced process automation, education and evolution of models of care and innovation around reimbursement and incentives for local manufacturing are concrete policy steps that can be taken.